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Zhaowei Zhu1†, Xianjin Wang1†, Zhoujun Shen1*, Yingli Lu2*, Shan Zhong1 and Chen Xu3,4Abstract
Background: Increasing evidence suggests that a history of diabetes mellitus (DM) may be associated with an
increased risk of bladder cancer. We performed a systematic review with meta-analysis to explore this relationship.
Methods: We identified studies by a literature search of Medline (from 1 January 1966) and EMBASE (from 1
January 1974), through 29 February 2012, and by searching the reference lists of pertinent articles. Summary relative
risks (RRs) with corresponding 95% confidence intervals (CIs) were calculated with a random-effects model.
Results: A total of 36 studies (9 case–control studies, 19 cohort studies and 8 cohort studies of patients with diabetes)
fulfilled the inclusion criteria. Analysis of all studies showed that DM was associated with an increased risk of bladder
cancer (the summary RR = 1.35, 95% CI 1.17–1.56, p < 0.001, I2 = 94.7%). In analysis stratified by study design, diabetes was
positively associated with risk of bladder cancer in case–control studies (RR = 1.45, 95% CI 1.13-1.86, p = 0.005, I2 = 63.8%)
and cohort studies (RR = 1.35, 95% CI 1.12-1.62, p < 0.001, I2 = 94.3%), but not in cohort studies of diabetic patients (RR =
1.25, 95% CI 0.86–1.81, p < 0.001, I2 = 97.4%). The RRs of bladder cancer were 1.38 (1.08-1.78) for men and 1.38 (0.90-2.10)
for women with diabetes, respectively. Noteworthy, the relative risk of bladder cancer was negatively correlated with the
duration of DM, with the higher risk of bladder cancer found among patients diagnosed within less than 5 years.
Conclusions: These findings support the hypothesis that men with diabetes have a modestly increased risk of bladder
cancer, while women with diabetes were not the case.
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Bladder cancer represents the first and second most
common genitourinary malignancy in China and the
USA, respectively. Based on incidence and mortality data
from several agencies, the American Cancer Society esti-
mates that 73,510 new bladder cancer cases and 14,880
deaths from bladder cancer are projected to occur in the
United States in 2012 [1]. To explore the effective tools
for prevention of bladder cancer, great investment has
been made to gain new insight into how environmental* Correspondence: shenzj6@sina.cn; 351192260@qq.com
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reproduction in any medium, provided the orand genetic factors influence the development of bladder
cancer. To date, several risk factors, such as paint, smok-
ing and human papillomavirus infection, have been im-
plicated in urinary bladder carcinogenesis [2-4].
Diabetes mellitus (DM) is considered to be one of the
major public health challenges in both industrialized and
developing countries [5]. The relationship between DM
and malignancies has been investigated extensively; and
ample evidence indicates that individuals with diabetes
have increased risk of several malignancies, including
cancers of the colon and rectum [6]. A clarification of
the association between DM and cancer is important for
disease prevention and management.
Diabetes may also be a risk factor for bladder cancer,
but findings from epidemiological studies are inconsistent.
A previous meta-analysis of 16 studies (7 case–control
studies, 3 cohort studies and 6 cohort studies of patients. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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was associated with an increased risk of bladder cancer in
case–control studies and cohort studies, but not in cohort
studies of patients with diabetes. However, a publication
bias against studies with small sample sizes and against
reporting a low relative risk is possible, and may have
resulted in an overestimation of the relationship between
diabetes and bladder cancer [7]. Besides, most studies in-
cluded in the meta-analysis were performed in Western
countries, and only one study was conducted in the Asian
population in Korea [8]. Thus, the association between
DM and bladder cancer in Asian population has not been
investigated extensively. Moreover, the association in dif-
ferent gender groups is worthy of investigation, but has
not been looked at.
Since the meta-analysis was published, a variety of relevant
studies on this association have also yielded inconsistent re-
sults. No association was found between DM and bladder
cancer in a prospective study of Swedish men [9]. However,
a case–control study in New England showed that history of
diabetes was related to an increased bladder cancer risk, and
the association was strongest in those who had diabetes for
the longest duration [10]. Currently, we aim to analyze this
relationship further by conducting an updated meta-analysis
of relevant studies. This updated analysis of 36 studies will
allow us to provide more precise risk estimates than the pre-
vious analysis. Furthermore, we also examined whether the
association between a history of DM and the risk of bladder
cancer differs according to various study characteristics.
Methods
Search strategy
A computerized literature search was performed in
Medline (from 1 January 1966) and EMBASE (from 1
January 1974), through 29 February 2012, by two inde-
pendent investigators. We searched the relevant studies
with the following text words and/or Medical Subject
Headings: ‘diabetes mellitus’, ‘diabetes’, ‘bladder cancer’,
‘urinary bladder neoplasms’, ‘transitional cell carcinoma
of the bladder’, and ‘epidemiologic studies’. The search
was restricted to articles published in English and
reporting on the association between diabetes and blad-
der cancer in humans. References of relevant review arti-
cles and trials were screened for relevant articles that
were not found through the database searches. Our system-
atic review was conducted according to the meta-analysis
of observational studies in epidemiology guidelines.
Selection criteria
In this meta-analysis, we included studies that fulfilled
the following criteria: (1) presented original data from
case-control or cohort studies; (2) one of the exposure
of interest was DM; (3) one of the outcome of interest
was bladder cancer; and (4) reported relative risk (RR),odds ratio, or standardized incidence/mortality rate
(SIR/SMR) with their 95% confidence intervals (CIs), or
provided sufficient information to calculate them. In the
event of multiple publications from the same study
population, the most recent publication with the largest
number of bladder cancer cases was included in the
meta-analysis. We did not consider studies in which the
exposure of interest was type 1 diabetes, which was de-
fined as early age (≤ 30 years) of diagnosis. Articles or
reports from non-peer-reviewed sources were not in-
cluded in our analysis.
Data extraction
Two investigators independently assessed and extracted
the data into a standardized data extraction form from
each publication. Disagreements were resolved by a third
author. We did not contact authors of the original stud-
ies in the case of missing data. Relevant data included
the first author’s last name, publication year, year of the
study conducted, study design, study location, source
population, sample size (cases and controls or cohort
size), measure of exposure and outcome, length of
follow-up (if applicable), variables adjusted in the ana-
lysis, and the risk estimates with corresponding 95% CIs.
If studies reported both incidence and mortality rate, we
extracted the incidence rate, as mortality rate could be
confounded by survival-related factors. From each study,
we extracted the RR estimate that was adjusted for the
greatest number of potential confounders.
Statistical analysis
We included in this meta-analysis studies reporting dif-
ferent measures of relative risks: rate ratio, hazard ratio
and SIR/SMR. In practice, these measures of effect yield
similar estimates of RR because the absolute risk of
bladder cancer is low. The variance of the log RR from
each study was calculated by converting the 95% CI to
its natural logarithm by taking the width of the CI and
dividing by 3.92. Summary relative risk estimates with
corresponding 95% CIs were derived using the method
of DerSimonian and Laird with the assumptions of a
random-effects model, which considers both within-
study and between-study variations. When sex-specific
estimates were available, we first analyzed together (as
RR estimates for bladder cancer) and then separately (as
RR estimates for cancers of different gender group).
In assessing heterogeneity among studies, we used the
Cochran Q test and I2 statistics. These were used to test
whether the differences obtained between studies were due
to chance. For the Q statistic, a p value of less than 0.10
was used as an indication of the presence of heterogeneity;
for I2, a value >50% was considered a measure of severe
heterogeneity. To explore the potential heterogeneity be-
tween studies, we conducted analyses stratified by study
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also evaluated the impact of adjustment for age, sex, smok-
ing, alcohol consumption, body mass index (BMI),physical
activity on the association between diabetes and the risk of
bladder cancer. Studies which reported separate RRs for
mutually exclusive categories of duration since diabetes was
diagnosed (e.g. < 5 years, ≥5 years) were pooled separately
to examine how the strength of the association varied with
duration of diabetes.
Publication bias was evaluated using a funnel plot of a
trial’s effect size against the SE. Because funnel plots
have several limitations and represent only an informal
approach to detect publication bias, we further carried
out formal testing using the test proposed by the Begg’s
adjusted rank correlation test and by the Egger’s regres-
sion test [11,12]. All statistical analyses were performed
using STATA, version 11.0 (STATA, College Station, TX,
USA). A two-tailed p-value of less than 0.05 was consid-
ered to be statistically significant.
Results
Search results
We identified 286 potentially relevant articles (Figure 1).
After exclusion of duplicate references, none-relevant lit-
erature, and those that did not satisfy inclusion criteria,
36 candidate articles were considered for the meta-
analysis, including nine case–control studies (Additional
file 1: Table S1) [10,13-20], 19 cohort studies (Additional
file 2: Table S2) [8,9,21-37] and eight cohort studies
(Additional file 3: Table S3) [38-45] of patients with dia-
betes using external population comparisons. Of these
studies, 12 studies were conducted in Europe, 13 in
North America, nine in Asia, and two in multiple coun-
tries. The study population in 31 studies consisted ofFigure 1 Flow chart on the articles selection process.men and women, four studies consisted entirely of men
and one study included women only. Among these 36
studies, 18 studies did not demonstrate a significantly in-
creased risk of bladder cancer in patients with DM, and
the rest studies reported a significantly increased risk of
bladder cancer in individuals with diabetes. Potential
confounders were controlled in most of the studies, ex-
cept in nine studies where the adjusted confounders
were not clearly indicated.DM and risk of bladder cancer
As shown in Figure 2, the summary RR with 95% CI was
1.35 (95% CI, 1.17–1.56) in a random-effects model for
patients with diabetes, compared with individuals with-
out DM. There was statistically significant heterogeneity
among these studies (Q = 660.30, P < 0.001, I2 = 94.7%).
In analysis stratified by study design, the summary RR
with 95% CI was 1.45 (95% CI, 1.13-1.86) and 1.35 (95%
CI, 1.35-1.62) in case–control and cohort studies, re-
spectively. However, diabetes was not associated with
risk of bladder cancer in cohort studies of patients with
diabetes (RR = 1.25; 95% CI, 0.86–1.81). There was sta-
tistically significant heterogeneity among the case–con-
trol studies (Q = 22.13, p = 0.005, I2 = 63.8%), the
cohort studies (Q = 315.87, p < 0.001, I2 = 94.3%) and
the studies of patients with diabetes (Q = 264.47,
p < 0.001, I2 = 97.4%).
We also investigated the impact of confounding fac-
tors on the estimates of relative risk (Additional file 4:
Table S4). The summary estimates were significantly
higher for studies conducted in Asia and North America
(p < 0.05) than in Europe and for studies published in
2000 or later than for studies published before 2000 (p <
0.05). The summary estimates were lower for studies
that reported age-adjusted RRs than for those which did
not [summary RR (95% CI); 1.34 (1.18-1.51) versus 1.60
(1.53-1.67)]. The summary estimates were higher for
studies that reported smoking-adjusted RRs than for
those which did not [summary RR (95% CI); 1.32 (1.24–
1.39) versus 1.26 (0.99–1.60)]. There was statistically sig-
nificant heterogeneity within most subgroups.DM and incidence of bladder cancer by sex
Fourteen studies provided results on cancer incidence or
mortality specific for gender; Additional four studies
consisted entirely of men and one study consisted en-
tirely of women. In stratified analyses by gender, a sig-
nificantly stronger positive association was observed in
men (summary RRs, 1.38; 95% CI, 1.08-1.78; p < 0.001
for heterogeneity). However, diabetes was not associated
with an increased risk of bladder cancer in women
(summary RRs, 1.38; 95% CI, 0.90-2.10; p < 0.001 for
heterogeneity) (Figure 3).
Figure 2 Forest plots of bladder cancer incidence/standard incidence rate associated with diabetes.
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The temporal sequence between diabetes and bladder
cancer has not always been clear. Three studies in
our meta-analysis presented with RRs for duration of
diabetes [10,24,33]. However, duration of diabetes
was not similar across the studies. Thus, we catego-
rized the patients into two groups, those with dia-
betes of less than 5 years and those with diabetes of
5 years or more. Combining these studies according
to diabetes duration, we found that individuals with
the shorter duration of diabetes (< 5 years) had
higher risk of developing bladder cancer thanindividuals who had duration of diabetes more than 5
years [summary RR, 95% CI; 1.52 (1.05–2.21) versus
1.08 (0.91–1.28)].Publication bias
There was no funnel plot asymmetry for the associ-
ation between DM and risk of bladder cancer. P values
for Begg’s adjusted rank correlation test was 0.989 and
the Egger’s regression asymmetry test was 0.284,
suggesting a low probability of publication bias
(Figure 4).
Figure 3 Forest plots of bladder cancer incidence/standard incidence rate by sex associated with diabetes.
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In this meta-analysis, we found that compared with non-
diabetics or general population, individuals with diabetes
may have more than 35% increased risk of bladder can-
cer. However, there were differences in the summary RR
among different study designs. Whereas diabetes was
positively associated with an increased risk of bladder
cancer in case–control and cohort studies, the summary
estimate in cohort studies of patients with diabetes did
not indicate an excess risk of bladder cancer in these
cases compared with the general population.
The strength of the study includes that, on an inter-
national scale, there are far more individuals with diabetes
in our study. After adjustment for important covariates,
our study extends previous meta-analysis by providing a
more precise estimate of the association between diabetes
and bladder cancer risk (based on 36 studies). Despitesimilar summary RRs between women and men, the posi-
tive association was only observed in men, and was inde-
pendent of BMI, alcohol consumption, smoking status
and physical activity. Lorente and colleagues found that
transitional cell carcinoma of the bladder was more fre-
quent in males than females. However, never-smoker
women have larger and more aggressive tumors with a
higher frequency of muscle-invasive disease than male
never-smokers and equaling to male current-smokers [46].
Moreover, women also had higher risk of invasive bladder
cancer than men even they smoked comparable amount of
cigarettes as men [47]. Further studies are needed to con-
firm our findings and to understand the molecular path-
ways that might explain the gender-related differences.
Furthermore, the relationship between duration of ex-
posure to diabetes and risk of bladder cancer could be
calculated by summing up data from different studies.
Figure 4 Funnel plot of observational studies evaluating the association between diabetes and bladder cancer risk.
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bladder cancer was inversely associated with the dur-
ation of DM. There was a slightly increased risk which
did not reach statistical significance among individuals
with diabetes more than 5 years and an increased rate of
bladder cancer was observed in individuals with a
shorter duration of diabetes (< 5 years). This finding in-
dicated that those with newly diagnosed diabetes should
be highly alert to bladder cancer development. However,
MacKenzie and colleagues found that compared with
those without diabetes, the risk of bladder cancer was
highest among those with diabetes of 16 years or more
[10]. It is worth noticing that only three studies in our
study presented with RRs for duration of diabetes
[10,24,33]. When the effect of diabetes was evaluated,
glucose-lowering therapies should be adjusted for, and
this was not done in most studies. With increasing dia-
betes duration, the impact of anti-diabetic drugs may set
in and influence the association. Thus, the long-term
risk of bladder cancer among patients with diabetes war-
rants further investigation.
In stratified analysis by geographic regions and publica-
tion year, we found that the association between DM and
bladder cancer was not significant for studies conducted
in Europe and for studies published from 1970–1999,
whereas studies from North American and Asia and stud-
ies published since 2000 showed significantly stronger risk
estimates. The regional and temporal differences are
perplexing. Many environmental and personal determi-
nants are related, including : genetic factors, lifestyle (eat-
ing habits, physical activities, somatotype characteristics),
environmental factors (environmental pollution, stress, so-
cioeconomic status ), public health services and so on.
With the gradual improvement of medical conditions,
early screening and diagnosis rates of DM and bladdercancer are greatly improved. These factors are all attribut-
able to the regional and temporal differences. Our study
also has several potential limitations of the available data.
Thus, caution is needed when interpreting these results.
First, great heterogeneity existed in terms of geographical
region, study design, publication year, gender, duration of
diabetes and adjustment for confounders. Despite the use
of appropriate meta-analytic techniques with random-
effect models, we could not account for these differences.
The heterogeneity of risk estimates may be due to differ-
ent mixtures of type 1 and type 2 participants with dia-
betes and different adjustment for potential confounders.
Moreover, some studies included both sexes, whereas
others included only men or only women. Nevertheless,
subgroup analyses showed that the risk estimate was ro-
bust across various quality components.
Second, because diabetes is an underdiagnosed disease,
some misclassification of exposure is likely, which would
tend to attenuate any true association between diabetes
and bladder cancer. In cohort studies of patients with
diabetes, the negative association between diabetes and
bladder cancer may be due to that the comparison group
includes individuals with diabetes, resulting in underesti-
mation of the true effect size.
Third, recent studies have suggested that use of
pioglitazone (a common anti-diabetic drug) was associ-
ated with an increased incidence of bladder cancer
[48,49]. However, most studies included in this meta-
analysis did not adjust for the effect of anti-diabetic
drugs, which may distort the true relationship between
diabetes and risk of bladder cancer.
Forth, confounding cannot be fully excluded as a po-
tential explanation for the observed association, because
our analyses were based on observational studies. It is
generally accepted that diabetes and bladder cancer
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ently been associated with increased risk of diabetes and
bladder cancer [50,51]. The relationship between dia-
betes and bladder cancer was stronger and statistically
significant when we restricted the analysis to those stud-
ies which controlled for smoking. When risk estimates
from the five studies that adjusted for physical activity
were combined, the association between diabetes and
bladder cancer was also stronger (RR 1.43) than the
overall result including all studies (RR 1.35). In the
current analysis, however, adjustment for a wide range
of potential confounders, including sex, BMI and alcohol
consumption, did not significantly alter the relationship
between diabetes and risk of bladder cancer.
Fifth, different study designs may have particular
methodological issues and constraints; yet, a common
theme with all is the potential for bias. Case–control
studies are susceptible to recall and selection biases
which could inflate the RRs. Cohort studies are prone to
be influenced by detection bias because patients with
diabetes are under increased medical surveillance. If
medical surveillance bias is present, bladder cancer
would tend to be diagnosed at an earlier stage in pa-
tients with diabetes than in those without diabetes.
Finally, inherent in any meta-analysis of published data
is the possibility of publication bias, that is small studies
with null results tend not to be published. However, the
results obtained from funnel plot analysis and formal
statistical tests did not provide evidence for such bias.
Although the absolute risks of bladder cancer are
low among individuals with diabetes, our results have
important clinical and public health significance. As a
serious and growing health problem in USA, DM
affects nearly 25.8 million people, 8.3% of the U.S.
population in 2010. In China, a cross-sectional study
from 2007 through 2008 involving a nationally repre-
sentative sample of 46,239 adults, the age-standardized
prevalences of total diabetes and prediabetes were 9.7
and 15.5%, respectively [52]. Due to growing obesity
epidemic, the prevalence of diabetes will probably
increase and contribute to the development of bladder
cancer.Conclusion
In conclusion, the results from this meta-analysis sup-
port an association between diabetes and increased risk
of bladder cancer. Further analysis indicates that the
positive association is only in men, but not in women.
More researches, both epidemiological and mechanistic,
are needed to further clarify the association between dia-
betes and risk of bladder cancer. Future work should
also focus on identifying the potential mechanisms
underlying this positive link.Additional files
Additional file 1: Table S1. Characteristics of nine case-control studies
of diabetes and bladder cancer risk.
Additional file 2: Table S2. Characteristics of 19 cohort studies of
diabetes and bladder cancer risk based on rate ratio and hazard ratio.
Additional file 3: Table S3. Characteristics of eight cohort studies of
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association between diabetes and bladder cancer risk.
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